Endocyte, Inc.
Aug 16, 2017
PDF
Add to Briefcase

Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition

WEST LAFAYETTE, Ind., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the 254th American Chemical Society (ACS) National Meeting & Exposition being held in Washington, DC, August 20-24, 2017.

"Our presentations will focus on the application of novel chemistries toward the synthesis of SMDCs for the treatment of cancer and inflammation, including EC2629, our folate-targeted PBD agent that simultaneously targets cancer cells and the tumor associated macrophages (TAMS) for which we recently filed an IND," said Iontcho Vlahov, Ph.D., vice president of discovery chemistry. "In our presentations, we will detail the syntheses of folate conjugates of bis-pro-PBDs as well as folate conjugates of pro-PBD hybrids with DNA minor groove binders, which employ cleavable disulfide or enzyme -responsive self-immolative linker systems. In addition, we will present the synthesis of novel folate-aminopterin conjugates, which employ a series of cysteine-derived linkers, which are reductively and/or enzymatically labile. Finally, we will present structure activity relationship (SAR) data on a new series of tubulysin analogs, and will detail the incorporation of one of these analogs into a folate conjugate."

Presentations are as follows:

Abstract # MEDI 87
Title: Design and synthesis of N-alkylated tubulysin analogs and their folate conjugates
When: Sunday, August 20, 2017 from 7:00 pm to 9:00 pm.
Session ID: General Poster Session
Location: Walter E. Washington Convention Center            
Room: Hall E

Abstract # MEDI 88
Title: Pro-Pyrrolobenzodiazepine (pro-PBD) bioconjugates, part 1:  Design and synthesis of pro-PBD conjugates containing a cleavable disulfide linker
When: Sunday, August 20, 2017 from 7:00 pm to 9:00 pm.
Session ID: General Poster Session
Location: Walter E. Washington Convention Center            
Room: Hall E

Abstract # MEDI 90
Title: Targeted folate-aminopterin anti-inflammatory conjugates:  Optimization of a reductively/enzymatically labile cysteine-derived linker system
When: Sunday, August 20, 2017 from 7:00 pm to 9:00 pm.
Session ID: General Poster Session
Location: Walter E. Washington Convention Center            
Room: Hall E

Abstract # MEDI 91
Title: Pro-Pyrrolobenzodiazepine (pro-PBD) bioconjugates, part 2:  Design and synthesis of pro-PBD conjugates containing an enzyme-responsive linker
When: Sunday, August 20, 2017 from 7:00 pm to 9:00 pm.
Session ID: General Poster Session
Location: Walter E. Washington Convention Center            
Room: Hall E

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In addition, the company continues to pursue applications of the SMDC platform and is working to bring assets toward clinical development in several areas, including EC2629, its dual-targeted DNA crosslinker drug that can attack both TAMs and cancer cells, and its CAR T-Cell SMDC adaptor platform. For additional information, please visit Endocyte's website at www.endocyte.com.

Contacts:

Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com

Primary Logo

Source: Endocyte, Inc.

News Provided by Acquire Media